Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 04, 2015 2:25 AM ET

Healthcare Providers and Services

Company Overview of Aurora Diagnostics, LLC

Company Overview

Aurora Diagnostics, LLC, a specialized laboratory company, provides unsurpassed diagnostic, prognostic, and therapeutic information and services to physicians, hospital systems, and researchers in the United States. It offers pathology services, such as dermatopathology, gastrointestinal and hepatic pathology, hematopathology, and genitourinary; and pathology services to women’s health care providerpathology. The company also provides molecular diagnostic services that focus on pharmacogenomics, oncology, women’s health, and infectious diseases; and hospital-based clinical and management solutions, such as anatomic and clinical, professional component, and technical component pathology servi...

11025 RCA Center Drive

Suite 300

Palm Beach Gardens, FL 33410

United States

Founded in 2006

1,102 Employees

Phone:

866-420-5512

Fax:

561-626-4530

Key Executives for Aurora Diagnostics, LLC

Chief Executive Officer and President
Age: 66
Executive Vice President of Sales & Marketing
Age: 44
Compensation as of Fiscal Year 2014.

Aurora Diagnostics, LLC Key Developments

Aurora Diagnostics, LLC Enters into Second Amendment to Financing Agreement

On April 10, 2015, Aurora Diagnostics Holdings, LLC entered into a second amendment to its financing agreement dated as of July 31, 2014, as amended, restated, supplemented or otherwise modified from time to time, by and among Aurora Diagnostics, LLC, as borrower, the company and certain subsidiaries of the borrower parties thereto, as guarantors, the various lenders from time to time party thereto, as lenders, and Cerberus Business Finance, LLC, as administrative agent and collateral agent. The second amendment provides for a new senior secured credit facility comprised of a $40 million delayed draw term loan B facility. The delayed draw term loan B facility is available for drawing from the second amendment effective date through April 10, 2016, and the proceeds thereof must be used to pay the consideration for (and fees and expenses relating to) permitted acquisitions (or to refinance revolving borrowings or replenish cash on hand used to consummate permitted acquisitions). The new senior secured credit facility has a maturity of July 31, 2019 but is subject to a maturity date of October 14, 2017 to the extent the company’s existing bonds are not refinanced or the maturity thereof extended prior to such date. The new senior secured credit facility is subject to the same amortization schedule, prepayment premiums and mandatory prepayment events as the other existing loans under the financing agreement. Additionally, the new senior secured credit facility is guaranteed by the same guarantors as the other existing loans under the financing agreement and is secured by the same collateral on a pari passu basis with such existing loans. Interest on all loans under the financing agreement is payable either quarterly or at the expiration of any LIBOR interest period applicable thereto. From and after the second amendment effective date, borrowings under the financing agreement accrue interest at a per annum rate equal to, at the borrower’s option, a base rate plus 6.125% or a LIBOR rate plus 7.125%. The loans are also subject to a 1.25% interest rate floor for LIBOR loans and a 2.25% interest rate floor for base rate loans. The new senior secured credit facility is subject to a 2.25% per annum fee on the undrawn amount thereof, payable quarterly in arrears. The second amendment contains customary representations and warranties applicable to the company and its subsidiaries. The new senior secured credit facility is subject to the same representations and warranties, affirmative and negative covenants and events of default as the existing loans under the financing agreement. If an event of default occurs under the term loan, the lenders may, among other remedies, accelerate the repayment of amounts outstanding under the new senior secured credit facility.

Aurora Diagnostics Announces New Credit Facility

Aurora Diagnostics announced that it has entered into a new five-year credit facility with Cerberus Business Finance, LLC effective July 31, 2014. The new agreement includes a $165,000,000 term loan and a $30,000,000 revolving credit line, as well as a $25,000,000 delayed draw term loan facility. Approximately $145,600,000 of the proceeds under the new credit facility were used to pre-pay all amounts outstanding under Aurora’s existing secured credit facility term loan and revolver. The balance of the proceeds under the new credit facility, including the availability under the revolving line of credit, will be used for potential future acquisitions and for Aurora’s general working capital and operational needs.

Aurora Diagnostics Reports Financial Results for the First Quarter Ended March 31, 2014

Aurora Diagnostics, LLC reported financial results for the first quarter ended March 31, 2014. Net revenue in the first quarter was $57 million compared to $61 million for the first quarter of the prior year, a decrease of approximately $4 million or 6%. Average revenue per accession decreased to $115 for the first quarter of 2014 from $117 for the same period in 2013, representing a $1.3 million reduction in net revenue. The decrease in the revenue per accession compared to the first quarter of '13 was primarily caused by reductions in Medicare reimbursement rates, including changes to the fee schedule effective January 1, 2014, and sequestration, which became effective April 1, 2013. Adjusted EBITDA was $7.6 million for the quarter ended March 31, 2014, compared to $7.7 million for the first quarter of 2013.

Similar Private Companies By Industry

Company Name Region
Seacoast Nursing And Rehabilitation Center, Inc United States
DDS Lab LLC United States
First Call Ambulance Service, LLC United States
Desert Neonatology Associates, P.C. United States
BioSoteria, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Aurora Diagnostics, LLC, please visit www.auroradx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.